Trial Profile

The Efficacy of Neoadjuvant PD-1 Plus Concurrent Chemotherapy for Stage II-IVA Operable Esophageal Squamous Cell Carcinoma A Single Armed, Open-label, Multicentre, Clinical Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 01 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Camrelizumab (Primary) ; Cisplatin (Primary) ; Paclitaxel (Primary)
Indications Oesophageal cancer; Squamous cell cancer
Focus Therapeutic Use

Most Recent Events

30 May 2022 Results assessing neoadjuvant camrelizumab plus chemotherapy in resectable, locally advanced esophageal squamous cell carcinoma patinets, published in the International Journal of Cancer
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
31 Jan 2021 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com